摩根大通分析师在最新研究报告中指出，艾伯维公司第二季度财报业绩超出市场预期。营收超预期表现颇为广泛——其中，Skyrizi和Rinvoq这两款药物的销售数据均小幅超过预估。分析师补充道："在接下来的业绩电话会上，我们将密切关注两大核心议题：其一，Skyrizi和Rinvoq的市场渗透率是否出现变化，以及针对这两款药物的最新业绩指引；其二，关于业务拓展方面的战略表态。"值得注意的是，艾伯维在早盘交易中下跌1%。此前，该公司下调了全年调整后盈利预期，主要归因于其对Apogee Therapeutics的收购交易。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.